Dr Robert Cutting

Dr Cutting has worked as a Consultant in Haematology since 2010, including overseas experience in New Zealand. He is currently employed at large Teaching Hospital in the North of England providing level 2A care to patients with haematological malignancy. He is currently Laboratory lead for haematology and haematology representative on the hospital VTE committee. Dr Cutting is also a reporter for the South Yorkshire Haemato-Oncology Diagnostic Service (HODS).

Dr Cutting has an interest in haematology malignancy, in particular the management of Myeloma and Lymphoma but also extensive experience in the diagnosis and management of myeloid malignancy (acute myeloid leukaemia and myelodysplasia), myeloproliferative disorders, and general benign haematology including management of difficult venous thromboembolism cases.

Dr Cutting read for the degree of MD at the Academic Unit of Child Health, University of Sheffield, and was awarded a Doctorate in Medicine (MD) in 2015. He has experience as principal investigator in a number of haematology-oncology trials. Dr Cutting holds a current Good Clinical Practice certification for participation in current clinical trials. Recent publications are referenced below.

Dr Cutting has nine years experience of clinical and educational supervision of trainees, has examined at undergraduate level and is involved in teaching and training of registrars in haematology.

Dr Cutting has contributed to the following publications in the past few years: CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Blood Adv. 2023 May 9;7(9):1672-1681 Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018 Oct;36(10):1143-1151

6

Dr Cutting is the Deputy Chair of the Haematology Cancer Delivery Group for South Yorkshire and North Trent (he is due to assume Chair in October 2023). Previously, he was the Deputy Chair and then Chair of the North Trent Network Site Specific Group (NSSG) responsible for improving cancer outcomes across the region. He is current laboratory lead for haematology and is current haematology representative on the hospital VTE committee. During his career he has held roles in chemotherapy governance, hospital VTE committee and as regional deputy chair for the myeloma MDT.

3